REMI vs SAFLY
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is REMI is a Hold and SAFLY is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
REMI’s FA Score shows that 0 FA rating(s) are green whileSAFLY’s FA Score has 0 green FA rating(s).
- REMI’s FA Score: 0 green, 5 red.
- SAFLY’s FA Score: 0 green, 5 red.
Price Growth
REMI (@Medical Specialties) experienced а 0.00% price change this week, while SAFLY (@Medical Specialties) price change was 0.00% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -4.23%. For the same industry, the average monthly price growth was -2.87%, and the average quarterly price growth was -6.14%.
Reported Earning Dates
REMI is expected to report earnings on Nov 27, 2024.
Industries' Descriptions
@Medical Specialties (-4.23% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| REMI | SAFLY | REMI / SAFLY | |
| Capitalization | 3.4M | 529M | 1% |
| EBITDA | -192.98K | 127M | -0% |
| Gain YTD | -48.454 | 69.434 | -70% |
| P/E Ratio | N/A | 9.32 | - |
| Revenue | 1.13M | 1.03B | 0% |
| Total Cash | 83.3K | 78.7M | 0% |
| Total Debt | 5.46K | 184M | 0% |
REMI | SAFLY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 41 Fair valued | 90 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 66 | |
SMR RATING 1..100 | 89 | 87 | |
PRICE GROWTH RATING 1..100 | 78 | 46 | |
P/E GROWTH RATING 1..100 | 53 | 65 | |
SEASONALITY SCORE 1..100 | n/a | 65 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
REMI's Valuation (41) in the null industry is somewhat better than the same rating for SAFLY (90). This means that REMI’s stock grew somewhat faster than SAFLY’s over the last 12 months.
SAFLY's Profit vs Risk Rating (66) in the null industry is somewhat better than the same rating for REMI (100). This means that SAFLY’s stock grew somewhat faster than REMI’s over the last 12 months.
SAFLY's SMR Rating (87) in the null industry is in the same range as REMI (89). This means that SAFLY’s stock grew similarly to REMI’s over the last 12 months.
SAFLY's Price Growth Rating (46) in the null industry is in the same range as REMI (78). This means that SAFLY’s stock grew similarly to REMI’s over the last 12 months.
REMI's P/E Growth Rating (53) in the null industry is in the same range as SAFLY (65). This means that REMI’s stock grew similarly to SAFLY’s over the last 12 months.
| RSI ODDS (%) |
| Stochastic ODDS (%) |
| Momentum ODDS (%) |
| MACD ODDS (%) |
| TrendWeek ODDS (%) |
| TrendMonth ODDS (%) |
| Advances ODDS (%) |
| Declines ODDS (%) |
| BollingerBands ODDS (%) |
| Aroon ODDS (%) |
REMI and
Correlation & Price change
A.I.dvisor tells us that REMI and AHICF have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that REMI and AHICF's prices will move in lockstep.
| Ticker / NAME | Correlation To REMI | 1D Price Change % | ||
|---|---|---|---|---|
| REMI | 100% | N/A | ||
| AHICF - REMI | 23% Poorly correlated | N/A | ||
| SNANF - REMI | 20% Poorly correlated | N/A | ||
| SAFLY - REMI | 7% Poorly correlated | N/A | ||
| RDGL - REMI | 3% Poorly correlated | -6.90% | ||
| SAFLF - REMI | 2% Poorly correlated | N/A | ||
More | ||||
SAFLY and
Correlation & Price change
A.I.dvisor indicates that over the last year, SAFLY has been loosely correlated with BIOQ. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if SAFLY jumps, then BIOQ could also see price increases.
| Ticker / NAME | Correlation To SAFLY | 1D Price Change % | ||
|---|---|---|---|---|
| SAFLY | 100% | N/A | ||
| BIOQ - SAFLY | 34% Loosely correlated | N/A | ||
| CNVVF - SAFLY | 32% Poorly correlated | N/A | ||
| TCHBF - SAFLY | 29% Poorly correlated | N/A | ||
| LZAGY - SAFLY | 28% Poorly correlated | -7.61% | ||
| CERS - SAFLY | 25% Poorly correlated | -4.44% | ||
More | ||||